FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023363514> ?p ?o ?g. }

• W2023363514 endingPage "66" @default.
• W2023363514 startingPage "62" @default.
• W2023363514 abstract "The results of an investigation to assess the clinical responses ofpatients with mild to moderate hypertension to a new combination formulation containing 75 mg triamterene and 50 mg hydrochlorothiazide are reported. One hundred fifty-six subjects entered the investigation. Subjects were divided into three groups, depending on whether they took two (group 1) or four capsules per day of a currently available formulation of triameterene and hydrochlorothiazide (Dyazide), or no antihypertensive medication prior to the start of the study. These medications were continued for an additional two weeks to generate baseline data. Thereafter, subjects received one tablet of the new combination formulation for four weeks. Seventy of the 156 participants received the new formulation for an additional period of at least 20 weeks. Observations during the study included sitting and standing pulse and blood pressure, weight, and serum electrolytes, uric acid, creatinine, and blood urea nitrogen levels. The results of the investigation indicated that subjects transferred to the new combination drug maintained normal serum electrolyte values, including potassium, with no or minor changes in the levels of uric acid, creatinine, and blood urea nitrogen. Reductions in systolic and diastolic blood pressure were observed in all three study groups, including subjects receiving two or four capsules of Dyazide per day in the two-week baseline period. We conclude that mild to moderately hypertensive subjects taking no medication or either two or four capsules of Dyazide per day may be transferred safely to the new combination product of triamterene and hydrochlothiazide. The results of an investigation to assess the clinical responses ofpatients with mild to moderate hypertension to a new combination formulation containing 75 mg triamterene and 50 mg hydrochlorothiazide are reported. One hundred fifty-six subjects entered the investigation. Subjects were divided into three groups, depending on whether they took two (group 1) or four capsules per day of a currently available formulation of triameterene and hydrochlorothiazide (Dyazide), or no antihypertensive medication prior to the start of the study. These medications were continued for an additional two weeks to generate baseline data. Thereafter, subjects received one tablet of the new combination formulation for four weeks. Seventy of the 156 participants received the new formulation for an additional period of at least 20 weeks. Observations during the study included sitting and standing pulse and blood pressure, weight, and serum electrolytes, uric acid, creatinine, and blood urea nitrogen levels. The results of the investigation indicated that subjects transferred to the new combination drug maintained normal serum electrolyte values, including potassium, with no or minor changes in the levels of uric acid, creatinine, and blood urea nitrogen. Reductions in systolic and diastolic blood pressure were observed in all three study groups, including subjects receiving two or four capsules of Dyazide per day in the two-week baseline period. We conclude that mild to moderately hypertensive subjects taking no medication or either two or four capsules of Dyazide per day may be transferred safely to the new combination product of triamterene and hydrochlothiazide." @default.
• W2023363514 created "2016-06-24" @default.
• W2023363514 creator A5014290342 @default.
• W2023363514 creator A5022473461 @default.
• W2023363514 creator A5048595867 @default.
• W2023363514 date "1984-11-01" @default.
• W2023363514 modified "2023-09-24" @default.
• W2023363514 title "Clinical experience with a new combination formulation of triamterene and hydrochlorothiazide (Maxzide) in patients with mild to moderate hypertension" @default.
• W2023363514 cites W1980923625 @default.
• W2023363514 cites W1982646165 @default.
• W2023363514 cites W1990737757 @default.
• W2023363514 cites W1992104685 @default.
• W2023363514 cites W2080508374 @default.
• W2023363514 cites W2081863225 @default.
• W2023363514 cites W2082256004 @default.
• W2023363514 cites W2088560296 @default.
• W2023363514 cites W2090928614 @default.
• W2023363514 cites W2415724942 @default.
• W2023363514 doi "https://doi.org/10.1016/s0002-9343(84)80010-8" @default.
• W2023363514 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6388328" @default.
• W2023363514 hasPublicationYear "1984" @default.
• W2023363514 type Work @default.
• W2023363514 sameAs 2023363514 @default.
• W2023363514 citedByCount "10" @default.
• W2023363514 crossrefType "journal-article" @default.
• W2023363514 hasAuthorship W2023363514A5014290342 @default.
• W2023363514 hasAuthorship W2023363514A5022473461 @default.
• W2023363514 hasAuthorship W2023363514A5048595867 @default.
• W2023363514 hasConcept C126322002 @default.
• W2023363514 hasConcept C126894567 @default.
• W2023363514 hasConcept C2777097880 @default.
• W2023363514 hasConcept C2777622974 @default.
• W2023363514 hasConcept C2778176769 @default.
• W2023363514 hasConcept C2779881121 @default.
• W2023363514 hasConcept C2779918671 @default.
• W2023363514 hasConcept C2780306776 @default.
• W2023363514 hasConcept C2780361556 @default.
• W2023363514 hasConcept C71924100 @default.
• W2023363514 hasConcept C84393581 @default.
• W2023363514 hasConceptScore W2023363514C126322002 @default.
• W2023363514 hasConceptScore W2023363514C126894567 @default.
• W2023363514 hasConceptScore W2023363514C2777097880 @default.
• W2023363514 hasConceptScore W2023363514C2777622974 @default.
• W2023363514 hasConceptScore W2023363514C2778176769 @default.
• W2023363514 hasConceptScore W2023363514C2779881121 @default.
• W2023363514 hasConceptScore W2023363514C2779918671 @default.
• W2023363514 hasConceptScore W2023363514C2780306776 @default.
• W2023363514 hasConceptScore W2023363514C2780361556 @default.
• W2023363514 hasConceptScore W2023363514C71924100 @default.
• W2023363514 hasConceptScore W2023363514C84393581 @default.
• W2023363514 hasIssue "5" @default.
• W2023363514 hasLocation W20233635141 @default.
• W2023363514 hasLocation W20233635142 @default.
• W2023363514 hasOpenAccess W2023363514 @default.
• W2023363514 hasPrimaryLocation W20233635141 @default.
• W2023363514 hasRelatedWork W131083658 @default.
• W2023363514 hasRelatedWork W1982574963 @default.
• W2023363514 hasRelatedWork W1990107430 @default.
• W2023363514 hasRelatedWork W2004107161 @default.
• W2023363514 hasRelatedWork W2023363514 @default.
• W2023363514 hasRelatedWork W2108354142 @default.
• W2023363514 hasRelatedWork W2351940717 @default.
• W2023363514 hasRelatedWork W2367160045 @default.
• W2023363514 hasRelatedWork W2395437808 @default.
• W2023363514 hasRelatedWork W2415791936 @default.
• W2023363514 hasVolume "77" @default.
• W2023363514 isParatext "false" @default.
• W2023363514 isRetracted "false" @default.
• W2023363514 magId "2023363514" @default.
• W2023363514 workType "article" @default.